Needham maintains Buy rating for Shattuck Labs stock at USD 19.00
Published on 10/05/2026 at 11:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Needham maintained its Buy rating and a USD 19.00 price target for Shattuck Labs stock, according to TradingView on October 2, 2026. The analyst target compares with a USD 6.84 closing reference cited in the note and gives the small-cap biotechnology company a sharply higher valuation benchmark.
Needham keeps a USD 19 target
The Needham note retained the Buy rating and set the target at USD 19.00, while describing SL-325 as a potential treatment for inflammatory and immune-mediated diseases. The target is a concrete counterweight to the company's clinical-stage risk because Shattuck has yet to establish commercial revenue.
The analyst view followed a new development step rather than a quarterly earnings surprise. That distinction matters for investors because the valuation case still depends on trial execution, regulatory progress and clinical data.
SL-325 enters another study
Shattuck announced plans on October 1, 2026, to evaluate SL-325 in a Phase 2 trial for moderate to severe hidradenitis suppurativa, according to StockTitan. Hidradenitis suppurativa becomes the second Phase 2 indication for the antibody, extending development beyond inflammatory bowel disease.
The RECEPTIVE-HS1 study is designed as a randomized, double-blind, placebo-controlled trial with a 16-week treatment period and an extension through Week 52. Shattuck expects an investigational new drug submission in October 2026 and Week 16 data in the first half of 2028, according to the same company release.
Losses keep the cash question central
Shattuck reported a USD 15.15 million net loss and adjusted? No, the reported figure is a GAAP net loss of USD 15.15 million, or USD 0.12 per share, for the second quarter of 2026, according to StockTitan. Cash, cash equivalents and short-term investments stood at USD 208.3 million on June 30, 2026, and the company expects that capital to fund operations into 2029.
The comparison is mixed: the second-quarter loss was larger than the USD 12.46 million loss reported for the comparable prior-year quarter, while the cash position supports continued development spending. For investors, the next value test is therefore clinical progress rather than near-term revenue growth.
Tradegate quote sets the snapshot
Shattuck Labs was last at EUR 5.96 on Tradegate on October 2, 2026, at 7:22 p.m. CEST, down 0.50 percent versus the Tradegate close of EUR 5.99 on October 1, 2026. Price source: substitute price Tradegate, Lang & Schwarz without data set.
Shattuck Labs stock facts
- Company: Shattuck Labs, Inc.
- ISIN: US82024L1035
- Ticker: STTK
- Primary exchange: Nasdaq
- Price substitute Tradegate (as of October 2, 2026, 7:22 p.m. CEST): EUR 5.96
- Change versus prior close: minus 0.50 percent
- Prior close Tradegate (October 1, 2026): EUR 5.99
- Market capitalization: USD 608.2 million (as of October 2, 2026)
- 52-week range: USD 1.70-8.33 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P Biotechnology Select Industry Index
